Literature DB >> 31092290

Comparison among ACR1997, SLICC and the new EULAR/ACR classification criteria in childhood-onset systemic lupus erythematosus.

Adriana Rodrigues Fonseca1, Marta Cristine Felix Rodrigues2, Flavio Roberto Sztajnbok2, Marcelo Gerardin Poirot Land3, Sheila Knupp Feitosa de Oliveira2.   

Abstract

BACKGROUND: To date there are no specific classification criteria for childhood-onset systemic lupus erythematosus (cSLE). This study aims to compare the performance among the American College of Rheumatology (ACR) 1997, the Systemic Lupus International Collaborating Clinics criteria (SLICC) and the new European League Against Rheumatism (EULAR)/ACR criteria, in a cSLE cohort.
METHODS: We conducted a medical chart review study of cSLE cases and controls with defined rheumatic diseases, both ANA positive, to establish each ACR1997, SLICC and EULAR/ACR criterion fulfilled, at first visit and 1-year-follow-up.
RESULTS: Study population included 122 cSLE cases and 89 controls. At first visit, SLICC criteria had higher sensitivity than ACR 1997 (89.3% versus 70.5%, p <  0.001), but similar specificity (80.9% versus 83.2%, p = 0.791), however performance was not statistically different at 1-year-follow-up. SLICC better scored in specificity compared to EULAR/ACR score ≥ 10 at first visit (80.9% versus 67.4%, p = 0.008) and at 1-year (76.4% versus 58.4%, p = 0.001), although sensitivities were similar. EULAR/ACR criteria score ≥ 10 exhibited higher sensitivity than ACR 1997 (87.7% versus 70.5%, p <  0.001) at first visit, but comparable at 1-year, whereas specificity was lower at first visit (67.4% versus 83.2%, p = 0.004) and 1-year (58.4% versus 76.4%, p = 0.002). A EULAR/ACR score ≥ 13 against a score ≥ 10, resulted in higher specificity, positive predictive value, and cut-off point accuracy. Compared to SLICC, a EULAR/ACR score ≥ 13 resulted in lower sensitivity at first visit (76.2% versus 89.3%, p <  0.001) and 1-year (91% versus 97.5%, p = 0.008), but similar specificities at both assessments. When compared to ACR 1997, a EULAR/ACR total score ≥ 13, resulted in no differences in sensitivity and specificity at both observation periods.
CONCLUSIONS: In this cSLE population, SLICC criteria better scored at first visit and 1-year-follow-up. The adoption of a EULAR/ACR total score ≥ 13 in this study, against the initially proposed ≥10 score, was most appropriate to classify cSLE. Further studies are necessary to address if SLICC criteria might allow fulfillment of cSLE classification earlier in disease course and may be more inclusive of cSLE subjects for clinical studies.

Entities:  

Keywords:  Adolescence; Childhood; Classification criteria; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2019        PMID: 31092290     DOI: 10.1186/s42358-019-0062-z

Source DB:  PubMed          Journal:  Adv Rheumatol        ISSN: 2523-3106


  10 in total

1.  Evaluation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in children and adults.

Authors:  Sang Cheng; Huihua Ding; Haiyan Xue; Lanfang Cao
Journal:  Clin Rheumatol       Date:  2022-07-19       Impact factor: 3.650

2.  Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematous in monogenic lupus.

Authors:  Sulaiman M Al-Mayouf; Lujayn Akbar; Reem Abdwani; Giulia Ginesi; Stefano Volpi; Marco Gattorno; Reima Bakry; Samia AlHashim; Alhanouf Alsaleem
Journal:  Clin Rheumatol       Date:  2022-05-19       Impact factor: 3.650

3.  Diagnostic dilemma in a 3-year-old girl with acute nephritic syndrome and hematologic abnormalities: Answers.

Authors:  Samantha Innocenti; Silvia Bernardi; Maud Prévot; Antonin Saldmann; Maud Tusseau; Alexandre Belot; Jean-Paul Duong Van Huyen; Olivia Boyer
Journal:  Pediatr Nephrol       Date:  2022-10-17       Impact factor: 3.651

4.  Autoimmune haemolytic anaemia and antiphospholipid antibodies in paediatrics: a systematic review and meta-analysis.

Authors:  Mira Merashli; Alessia Arcaro; Maria Graf; Fabrizio Gentile; Paul R J Ames
Journal:  Clin Rheumatol       Date:  2020-10-02       Impact factor: 2.980

5.  Autosomal Recessive ISG15 Deficiency Underlies Type I Interferonopathy with Systemic Lupus Erythematosus and Inflammatory Myositis.

Authors:  Sulaiman M Al-Mayouf; Lujayn Akbar; Abdullatif AlEnazi; Hamoud Al-Mousa
Journal:  J Clin Immunol       Date:  2021-03-19       Impact factor: 8.317

Review 6.  Systemic Lupus Erythematosus in Children and Young People.

Authors:  A Charras; E Smith; C M Hedrich
Journal:  Curr Rheumatol Rep       Date:  2021-02-10       Impact factor: 4.592

7.  CD4+ T-cell cooperation promoted pathogenic function of activated naïve B cells of patients with SLE.

Authors:  Kittikorn Wangriatisak; Piyawan Kochayoo; Pongsakorn Thawornpan; Chaniya Leepiyasakulchai; Thanitta Suangtamai; Pintip Ngamjanyaporn; Ladawan Khowawisetsut; Prasong Khaenam; Prapaporn Pisitkun; Patchanee Chootong
Journal:  Lupus Sci Med       Date:  2022-09

8.  Stand-alone renal SLICC criterion with full house glomerular deposits: is it enough for childhood lupus nephritis?

Authors:  Abdulaziz Almutairi; Hadeel Aljammz; Turki Al-Hussain; Sulaiman M Al-Mayouf
Journal:  Clin Rheumatol       Date:  2019-10-21       Impact factor: 2.980

9.  An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Vitor Cavalcanti Trindade; Magda Carneiro-Sampaio; Eloisa Bonfa; Clovis Artur Silva
Journal:  Paediatr Drugs       Date:  2021-07-10       Impact factor: 3.022

10.  Limited sensitivity and specificity of the ACR/EULAR-2019 classification criteria for SLE in JSLE?-observations from the UK JSLE Cohort Study.

Authors:  Eve M D Smith; Sajida Rasul; Coziana Ciurtin; Eslam Al-Abadi; Kate Armon; Kathryn Bailey; Mary Brennan; Janet Gardner-Medwin; Kirsty Haslam; Daniel P Hawley; Steven Lane; Alice Leahy; Valentina Leone; Gulshan Malik; Devesh Mewar; Robert Moots; Clarissa Pilkington; Athimalaipet V Ramanan; Satyapal Rangaraj; Annie Ratcliffe; Phil Riley; Ethan Sen; Arani Sridhar; Nick Wilkinson; Michael W Beresford; Liza J McCann; Christian M Hedrich
Journal:  Rheumatology (Oxford)       Date:  2021-11-03       Impact factor: 7.580

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.